Efforts on the part of New York pharma major Pfizer (NYSE: PFE) to become a vaccines giant took another step forward on Thursday, with positive results from a trial in meningitis.
Pfizer is developing a unique pentavalent vaccine, MenABCWY, which addresses all five of the meningitis variants that cause the majority of meningococcal disease.
Top-line data show the Phase III trial, which has been evaluating the vaccine in adolescents and young adults, met all primary and secondary endpoints.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze